期刊文献+

巴洛沙星片治疗泌尿系统细菌性感染的多中心随机双盲对照临床试验 被引量:3

A multicenter,randomized,and double-blind controlled clinical trial of balofloxacin in treatment of bacterial urinary tract infections
下载PDF
导出
摘要 目的评价巴洛沙星片治疗泌尿系统急性细菌性感染的安全性和有效性。方法采用多中心、双盲双模拟、随机、阳性药物平行对照试验设计。共入选221例,其中可评价疗效病例209例,巴洛沙星组102例,左氧氟沙星组107例。巴洛沙星组予巴洛沙星片200 mg,hid,左氧氟沙星组予左氧氟沙星片200 mg,bid,2组疗程均为7~14 d。结果巴洛沙星组临床总有效率和痊愈率分别为98.0%和87.2%,细菌清除率为100%;左氧氟沙星组临床总有效率和痊愈率分别为100.0%和87.9%,细菌清除率为100%。巴洛沙星组和左氧氟沙星组药物不良反应发生率分别为4.8%和0.9%。2组比较均无显著差异(P>0.05)。结论巴洛沙星治疗急性细菌性泌尿系统感染安全、有效。 AIM To evaluate the clinical efficacy and safety of domestic balofloxacin in the treatment of acute bacterial urinary tract infections. METHODS A randomized, double-blind controlled, and positive drug paralled clinical trial was conducted. Two hundred and twenty-one patients were enrolled with only 209 suitable for efficacy evalution including 102 patients in the balofloxacin group (balofloxacin 200 rag, bid) and 107 for the the levofloxacin group (levofloxacin 200 rag, bid) with 7 - 14 days as acourse for both groups. The overall clinical efficacy rates, cure rates, and bacterial clearance rates were 98.0 %, 87.2 % and 100 %; versus 100 %, 87.9 % and 100 % for balofloxacin group, levofloxacin group respectively; including the adverse drag reaction rates as 4.8 % and 0.9 % respectively. There were no statistical differences between the two groups (P 〉 0.05) . CONCLUSION Domestic balofloxacin is effective and safe for the treatment of acute bacterial urinary tract infections.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2008年第10期732-735,共4页 Chinese Journal of New Drugs and Clinical Remedies
关键词 巴洛沙星 泌尿道感染 革兰阳性菌感染 革兰阴性菌感染 随机对照试验 多中心研究 balofloxacin urinary tract infections gram-positive bacterial infections gram-negative bacterial infections randomized controlled trials multicenter studies
  • 相关文献

参考文献4

  • 1KAWAHARA S, TADA A, NAGARE H. In vitro antimycobacterial activities of a new quinolone, balofloxacin [J]. Kekkaku, 200l, 76(1): 29-31.
  • 2OBANA M, IRIMAJIRI S, TOMIZAWA 1, et ol. Clinical study of balofloxaein on infectious enteritis and assessment of the fecal drug concentration and intestinal microbial flora in patients with inpatients with infectious enteritis [J]. Kansenshogaku Zasshi, 1995, 69(9): 991-1006.
  • 3FUKUYAMA M, KAWAKAMI K, SUDA O, et al. In vitro antibacterial activity of balofloxacin (BLFX)against isolates from patients with bacterial enteritis[J]. Kansenshogaku Zasshi, 1995, 69(9): 987-990.
  • 4姚钢炼,廖婷婷,桂保松,马力群,张星映,周琳.巴洛沙星片治疗急性泌尿系统感染105例的随机对照研究[J].中国新药与临床杂志,2007,26(9):653-656. 被引量:6

二级参考文献9

  • 1袁喆,肖永红,张唯力,王长征,金欢胜.加替沙星与左氧氟沙星随机双盲对照治疗泌尿系统感染98例[J].中国新药与临床杂志,2004,23(11):753-757. 被引量:16
  • 2糜志远,刘万忠.新氟喹诺酮类抗生素巴洛沙星研究进展[J].中国新药杂志,2005,14(9):1205-1210. 被引量:21
  • 3ALKSNE L.Balofloxacin choongwae[J].Curr Opin Investig Drugs,2003,4(2):224-229.
  • 4王永利.人工合成抗菌药[M]//杨世杰.药理学.北京:人民卫生出版社,2001:88-89.
  • 5KOZAWAO,UEMATSU T,MATSUNO H,et al.Comparative study of pharmacokinetics of two new fluoroquinolones,balofloxacin and grepafloxacin,in elderly subjects[J].Antimicrob Agents Chemother,1996,40(12):2824-2828.
  • 6IWASAKI H,MIYAZAKI S,TSUJI A,et al.In vitro and in vivo antibacterial activities of Q-35,a novel fluoroquinolone[J].Chemotherapy,1995,41(2):100-112.
  • 7KAWAHARA S,TADA A,NAGARE H.In vitro antimycobacterial activities of a new quinolone,balofloxacin[J].Kekkaku,2001,76(1):29-31.
  • 8RUBINESTEIN E.History of quinolones and their side effects[J].Chemotherapy,2001,47 Suppl 3:3-8.
  • 9廖斌,丛欣,廖清江.2002年世界上市的新药[J].药学进展,2003,27(3):190-192. 被引量:17

共引文献5

同被引文献15

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部